Heartflow (NASDAQ:HTFL) Insider Sells $987,052.30 in Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 19,682 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $50.15, for a total value of $987,052.30. Following the completion of the transaction, the insider owned 79,956 shares of the company’s stock, valued at approximately $4,009,793.40. The trade was a 19.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

• On Monday, August 17th, Campbell Rogers sold 9,219 shares of Heartflow stock. The shares were sold at an average price of $41.23, for a total value of $380,099.37.

Heartflow Trading Down 5.5%

Shares of NASDAQ:HTFL opened at $47.39 on Thursday. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $52.22. The company has a market cap of $4.12 billion and a PE ratio of -25.90. The company’s 50 day moving average is $39.13 and its 200 day moving average is $32.28.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. Equities research analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. increased their price target on Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. Robert W. Baird set a $45.00 price objective on Heartflow in a report on Friday, August 14th. UBS Group began coverage on Heartflow in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $55.00 target price on the stock. Stifel Nicolaus raised their target price on Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Finally, Freedom Capital raised Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.25.

Hedge Funds Weigh In On Heartflow

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Engineers Gate Manager LP purchased a new stake in shares of Heartflow during the second quarter worth about $590,000. Integrated Wealth Concepts LLC purchased a new position in Heartflow in the 2nd quarter valued at about $53,000. Squarepoint Ops LLC boosted its holdings in Heartflow by 72.0% in the 2nd quarter. Squarepoint Ops LLC now owns 87,052 shares of the company’s stock worth $2,554,000 after buying an additional 36,441 shares during the last quarter. Arizona State Retirement System purchased a new stake in Heartflow during the 2nd quarter worth approximately $312,000. Finally, Allianz Asset Management GmbH acquired a new position in shares of Heartflow during the second quarter valued at approximately $1,557,000.

About Heartflow

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).